Wordt geladen...
Flaws in design, analysis and interpretation of Pfizer's antifungal trials of voriconazole and uncritical subsequent quotations
We have previously described how a series of trials sponsored by Pfizer of its antifungal drug, fluconazole, in cancer patients with neutropenia handicapped the control drug, amphotericin B, by flaws in design and analysis. We describe similar problems in two pivotal trials of Pfizer's new anti...
Bewaard in:
| Hoofdauteurs: | , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
BioMed Central
2006
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1399447/ https://ncbi.nlm.nih.gov/pubmed/16542031 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1745-6215-7-3 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|